Key facts
- This page summarizes Gregory H. Bailey's Form 4 filing for Biohaven Ltd. (BHVN).
- 15 reported transactions and 9 derivative rows are listed below.
- Accepted by SEC: 05 Oct 2022, 17:35.
Gregory H. Bailey - 03 Oct 2022 Form 4 Insider Report for Biohaven Ltd. (BHVN)
- Reporting relationship
- Director
- Issuer ticker
- BHVN
- Reported as of
- 03 Oct 2022
- Net transaction value
- -$13.66
- SEC form
- 4
- Accepted by SEC
- 05 Oct 2022, 17:35:20 UTC
- Prior SEC filing
- 30 Sep 2022
- Next SEC filing
- 26 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ George Clark, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gregory H. Bailey filed Form 4 for Biohaven Ltd. (BHVN) on 05 Oct 2022.
Change
- Previous filing in this sequence was filed on 30 Sep 2022.
- Current net transaction value: -$13.66.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BHVN
transaction
Common Shares
Other
- Transaction value
- $0
- Shares
- +1,291,829
- Change %
- Price
- $0.000000
- Shares after
- 1,291,829
- Date
- 03 Oct 2022
- Ownership
- Direct
- Footnotes
- F1
BHVN
transaction
Common Shares
Options Exercise
- Transaction value
- $19,936
- Shares
- +4,119
- Change %
- +0.32%
- Price
- $4.84
- Shares after
- 1,295,948
- Date
- 03 Oct 2022
- Ownership
- Direct
BHVN
transaction
Common Shares
Options Exercise
- Transaction value
- $21,353
- Shares
- +5,998
- Change %
- +0.46%
- Price
- $3.56
- Shares after
- 1,301,946
- Date
- 03 Oct 2022
- Ownership
- Direct
BHVN
transaction
Common Shares
Options Exercise
- Transaction value
- $20,970
- Shares
- +9,000
- Change %
- +0.69%
- Price
- $2.33
- Shares after
- 1,310,946
- Date
- 03 Oct 2022
- Ownership
- Direct
BHVN
transaction
Common Shares
Options Exercise
- Transaction value
- $27,540
- Shares
- +9,000
- Change %
- +0.69%
- Price
- $3.06
- Shares after
- 1,319,946
- Date
- 03 Oct 2022
- Ownership
- Direct
BHVN
transaction
Common Shares
Tax liability
- Transaction value
- $89,812
- Shares
- -11,975
- Change %
- -0.91%
- Price
- $7.50
- Shares after
- 1,307,971
- Date
- 03 Oct 2022
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BHVN
transaction
Derivative
Stock Options (Right to Buy)
Other
- Transaction value
- Shares
- +4,119
- Change %
- Price
- Shares after
- 4,119
- Date
- 03 Oct 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 4,119
- Exercise price
- $4.84
- Footnotes
- F3
BHVN
transaction
Derivative
Stock Options (Right to Buy)
Other
- Transaction value
- Shares
- +5,998
- Change %
- Price
- Shares after
- 5,998
- Date
- 03 Oct 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 5,998
- Exercise price
- $3.56
- Footnotes
- F3
BHVN
transaction
Derivative
Stock Options (Right to Buy)
Other
- Transaction value
- Shares
- +9,000
- Change %
- Price
- Shares after
- 9,000
- Date
- 03 Oct 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 9,000
- Exercise price
- $2.33
- Footnotes
- F3
BHVN
transaction
Derivative
Stock Options (Right to Buy)
Other
- Transaction value
- Shares
- +9,000
- Change %
- Price
- Shares after
- 9,000
- Date
- 03 Oct 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 9,000
- Exercise price
- $3.06
- Footnotes
- F3
BHVN
transaction
Derivative
Stock Options (Right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -4,119
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 03 Oct 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 4,119
- Exercise price
- $4.84
- Footnotes
- F3
BHVN
transaction
Derivative
Stock Options (Right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -5,998
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 03 Oct 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 5,998
- Exercise price
- $3.56
- Footnotes
- F3
BHVN
transaction
Derivative
Stock Options (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -9,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 03 Oct 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 9,000
- Exercise price
- $2.33
- Footnotes
- F3
BHVN
transaction
Derivative
Stock Options (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -9,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 03 Oct 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 9,000
- Exercise price
- $3.06
- Footnotes
- F3
BHVN
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +125,000
- Change %
- Price
- $0.000000
- Shares after
- 125,000
- Date
- 03 Oct 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 125,000
- Exercise price
- $7.00
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer").
Footnote F2
These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options.
Footnote F3
Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.
Footnote F4
The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date